Back to search results

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Abroad (travel likely)RecruitingPHASE1

Conditions

Gastroesophageal Cancer (GC) · Hepatocellular Carcinoma (HCC) · Endometrial Cancer · Renal Cell Carcinoma (RCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Haeseong Park, MD) · Haeseong_park@dfci.harvard.edu · 617-632-4500
    Contact: Principal Investigator (Haeseong Park, MD)

  • Nebraska Cancer Specialists, Omaha, Nebraska, United States

    Contact: Study coordinator (Ashley Servais) · aservais@nebraskacancer.com · 402-955-2691
    Contact: Principal Investigator (Ralph Hauke, MD)

  • START New York, Lake Success, New York, United States

    Contact: Study coordinator (Camilita Goberdhan) · camilita.goberdhan@startresearch.com · 347-476-1959
    Contact: Principal Investigator (Geraldine O'Sullivan Coyne, MD, PhD)

  • Prisma Health Cancer Institute, Greenville, South Carolina, United States

    Contact: Study coordinator (Jeff Edenfield, MD) · jeffery.edenfield@prismahealth.org · 864-455-3600
    Contact: Principal Investigator (Jeff Edenfield, MD)

  • SCRI Oncology Partners, Nashville, Tennessee, United States

    Contact: Study coordinator (Meredith Pelster, MD) · meredith.pelster@scri.com · 844-482-4812
    Contact: Principal Investigator (Meredith Pelster, MD)
Study leads

  • Cynthia Sirard, MD

    Study Director

    Compass Therapeutics

View source on ClinicalTrials.gov(opens in a new tab)